Elafibranor in primary biliary cholangitis: Two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial

医学 内科学 碱性磷酸酶 交叉研究 胃肠病学 随机对照试验 临床试验 患者数据 不利影响 规范化(社会学) 临床研究阶段 外科 疾病严重程度 初级保健
作者
Kris V. Kowdley,Christopher L. Bowlus,Cynthia Levy,Ulus Salih Akarca,Mário Reis Álvares‐da‐Silva,Pietro Andreoné,Marco A. Arrese,Christophe Corpechot,Hany A. Elbeshbeshy,Sven Francque,Michael A. Heneghan,Pietro Invernizzi,Ira M. Jacobson,David E. Jones,Andreas Emanuel Kremer,Frederik Cornelius Kruger,Marcelo Kugelmas,Eric Lawitz,Marlyn J. Mayo,Mitchell L. Shiffman
出处
期刊:Journal of Hepatology [Elsevier BV]
被引量:1
标识
DOI:10.1016/j.jhep.2026.08.016
摘要

BACKGROUND & AIMS: We report 104-week placebo-controlled data and long-term open-label extension (OLE) data from the ongoing ELATIVE® phase III trial (NCT04526665) of elafibranor in primary biliary cholangitis (PBC). METHODS: A total of 161 patients were randomized 2:1 to elafibranor 80 mg or placebo. The double-blind period (DBP) consisted of 52-week common (Part 1) and variable (Part 2) periods. Patients completing Part 1 continued into Part 2 until all patients completed Part 1, or for a maximum of 104 weeks. All patients completing Part 1 could enter the OLE and receive elafibranor. RESULTS: At Week 104 in DBP Part 2, 64.3% (18/28) and 10.7% (3/28) of elafibranor-treated patients achieved biochemical response and alkaline phosphatase (ALP) normalization, respectively, vs. no placebo-treated patients. In patients with moderate-to-severe fatigue or pruritus at baseline, mean (SE) changes to Week 104 in PROMIS Fatigue Short Form 7a (PFSF 7a) and PBC Worst-Itch Numeric Rating Scale (PBC WI NRS) were -6.3 (2.2) vs. -0.4 (1.2) and -4.1 (1.0) vs. 0.3 (1.2), respectively, with elafibranor vs. placebo. A total of 138 patients entered the OLE (continuous elafibranor: n = 93; crossover elafibranor: n = 45). Among patients continuing elafibranor, 58.8% (47/80) and 65.0% (13/20) achieved biochemical response, and 15.0% (12/80) and 25.0% (5/20) achieved ALP normalization at Weeks 104 and 156, respectively. In crossover patients, 51.2% (21/41) and 22.0% (9/41) achieved biochemical response and ALP normalization after 52 weeks, respectively. In patients continuing elafibranor with moderate-to-severe symptoms at baseline, mean (SE) changes to Week 130 in PFSF 7a and PBC WI NRS were -4.8 (1.5) and -4.0 (0.7), respectively. There were no unexpected safety findings. CONCLUSIONS: Through 3 years of treatment, elafibranor led to sustained biochemical improvements and was generally well tolerated, with numerical improvements in fatigue and pruritus. IMPACT AND IMPLICATIONS: Given the chronic, progressive nature of primary biliary cholangitis (PBC), the long-term efficacy and tolerability of treatments is important. Here, we present 2-year results from the double-blind period, and long-term data from the ongoing open-label extension of the phase III ELATIVE® trial, wherein elafibranor (a peroxisome proliferator-activated receptor-α/δ agonist) treatment led to sustained biochemical improvements, stable non-invasive tests of fibrosis, and numerical improvements in fatigue and pruritus, through 3 years. Elafibranor demonstrated a favorable safety profile up to a maximum treatment exposure of 3.5 years, including in patients crossing over from placebo. These findings support elafibranor as a durable long-term treatment for patients with PBC, and are particularly relevant for clinicians managing patients with inadequate response or intolerance to first-line treatments. TRIAL REGISTRATION: NCT04526665 (https://clinicaltrials.gov/study/NCT04526665); first registered 08/26/2020.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Harry发布了新的文献求助10
刚刚
ZJ发布了新的文献求助10
刚刚
沂安发布了新的文献求助10
刚刚
小蘑菇的应助被wangxia采纳,获得10
1秒前
喵不二完成签到 ,获得积分10
1秒前
科研通AI6.3的应助被lkn采纳,获得10
2秒前
泥头车发布了新的文献求助10
2秒前
3秒前
3秒前
suicone发布了新的文献求助10
3秒前
研友_VZG7GZ的应助被jackson_WANG采纳,获得10
3秒前
daomaihu发布了新的文献求助100
4秒前
我是老大的应助被时思采纳,获得10
4秒前
范Fine发布了新的文献求助10
5秒前
Jasper的应助被永远喜欢一点点采纳,获得10
6秒前
研友_LmeK4L发布了新的文献求助10
8秒前
8秒前
Youdge的应助被Tuniverse_采纳,获得20
9秒前
9秒前
mairs完成签到 ,获得积分10
10秒前
Ava的应助被cen采纳,获得10
11秒前
懿生完成签到,获得积分10
11秒前
大橙子完成签到,获得积分20
11秒前
12秒前
desperado发布了新的文献求助10
13秒前
李涵睿发布了新的文献求助10
14秒前
玩意儿完成签到,获得积分10
14秒前
15秒前
认真的长颈鹿完成签到,获得积分10
15秒前
16秒前
英姑的应助被yn107采纳,获得10
17秒前
搜集达人的应助被12ins采纳,获得10
18秒前
不染完成签到,获得积分20
18秒前
jason完成签到,获得积分20
19秒前
19秒前
daomaihu发布了新的文献求助100
19秒前
西西完成签到 ,获得积分10
20秒前
Caurmosi完成签到,获得积分10
20秒前
今天就Accept完成签到,获得积分10
20秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183403
求助须知:如何正确求助?哪些是违规求助? 9572654
关于积分的说明 21826992
捐赠科研通 7780463
什么是DOI,文献DOI怎么找? 3434008
关于科研通互助平台的介绍 2558183
邀请新用户注册赠送积分活动 2480337